0858.HK

Extrawell Pharmaceutical Holdings Limited [0858.HK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

0858.HK Stock Summary

Earnings are expected to fall -100% next year

0858.HK has less than 1 year of cash runway

Top 10 Correlated ETFs

0858.HK

Top 10 Correlated Stocks

0858.HK

In the News

0858.HK Financial details

Company Rating

Buy

Market Cap

78.87M

Income

129.27M

Revenue

72.58M

Book val./share

0.43

Cash/share

0.03

Dividend

Dividend %

Employees

169

Optionable

Shortable

Yes

Earnings

29 Nov 2023

P/E

0.93

Forward P/E

PEG

-0.48

P/S

1.42

P/B

0.08

P/C

1.1

P/FCF

-21.24

Quick Ratio

1.83

Current Ratio

3.13

Debt / Equity

0.08

LT Debt / Equity

0.08

EPS (TTM)

0.04

EPS next Y

EPS next Q

EPS this Y

-0.92%

EPS next Y

EPS next 5Y

EPS last 5Y

15.08%

Revenue last 5Y

-4.04%

Revenue Q/Q

EPS Q/Q

SMA20

-25%

SMA50

-40%

SMA100

-40%

Inst Own

Inst Trans

ROA

ROE

10%

ROC

-0.01%

Gross Margin

44%

Oper. Margin

-13%

Profit Margin

192%

Payout

Shs Outstand

2.39B

Shs Float

945.51M

Target Price

52W Range

0.031-0.104

52W High

52W Low

RSI

37.77

Rel Volume

4.27

Avg Volume

787.42K

Volume

3.36M

Perf Week

-5.71%

Perf Month

-21.43%

Perf Quarter

-40%

Perf Half Y

-42.11%

Beta

0.472

Volatility

0%, 0%

Prev Close

Price

0.033

Change

-2.94%

0858.HK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.04	0.03	0.03	0.03	0.02
Net income per share	0.03	0.03	-0.05	0.05	0.04
Operating cash flow per share	-0.01	-0.01	0	0	0
Free cash flow per share	-0.01	-0.01	0	0	0
Cash per share	0.06	0.05	0.05	0.05	0.04
Book value per share	0.45	0.48	0.43	0.49	0.44
Tangible book value per share	0.44	0.48	0.43	0.49	0.44
Share holders equity per share	0.45	0.48	0.43	0.49	0.44
Interest debt per share	0.02	0.03	0.04	0.04	0.04
Market cap	253.34M	215.1M	372.84M	207.93M	196.77M
Enterprise value	154.07M	153.2M	320M	181.36M	197.6M
P/E ratio	3.96	2.58	-3.08	1.59	1.52
Price to sales ratio	2.84	2.77	4.73	2.81	2.71
POCF ratio	-16.79	-16.23	-437.61	-117.74	166.76
PFCF ratio	-15.35	-16.04	-237.02	-18.25	-36.19
P/B Ratio	0.24	0.19	0.36	0.18	0.15
PTB ratio	0.24	0.19	0.36	0.18	0.15
EV to sales	1.73	1.97	4.06	2.45	2.72
Enterprise value over EBITDA	-135.87	43.4	190.93	-28.53	-57.81
EV to operating cash flow	-10.21	-11.56	-375.59	-102.69	167.45
EV to free cash flow	-9.34	-11.42	-203.44	-15.92	-36.34
Earnings yield	0.25	0.39	-0.32	0.63	0.66
Free cash flow yield	-0.07	-0.06	0	-0.05	-0.03
Debt to equity	0.05	0.06	0.07	0.07	0.08
Debt to assets	0.04	0.05	0.06	0.06	0.07
Net debt to EBITDA	87.54	-17.54	-31.53	4.18	-0.24
Current ratio	2.62	3.58	3.65	3.03	3.13
Interest coverage	-2.17	-0.86	-0.97	-0.98	-0.72
Income quality	-0.24	-0.15	0.01	-0.01	0.01
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.3	0.34	0.3	0.33	0.35
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.01	0	0	0	0
Capex to operating cash flow	0.09	0.01	0.85	5.45	-5.61
Capex to revenue	-0.02	0	-0.01	-0.13	-0.09
Capex to depreciation	-0.22	-0.03	-0.09	-1.1	-0.75
Stock based compensation to revenue	0	0	0	0	0
Graham number	0.52	0.61	0.7	0.77	0.66
ROIC	-0.02	-0.01	-0.01	-0.01	-0.01
Return on tangible assets	0.05	0.07	-0.1	0.1	0.09
Graham Net	0.01	0	0	-0.01	-0.02
Working capital	128.9M	150.76M	153.19M	130.32M	121.65M
Tangible asset value	1.05B	1.14B	1.03B	1.16B	1.28B
Net current asset value	74.13M	83.23M	76.14M	42.21M	15.36M
Invested capital	0.05	0.06	0.07	0.07	0.08
Average receivables	0	0	0	0	0
Average payables	7.52M	7.18M	6.47M	6.57M	6.55M
Average inventory	4.96M	5.84M	6.71M	8.01M	5.74M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	74.86	65.69	67.41	64.79	58.44
Days of inventory on hand	53.66	61.75	76.13	84.95	26.59
Receivables turnover	0	0	0	0	0
Payables turnover	4.88	5.56	5.41	5.63	6.25
Inventory turnover	6.8	5.91	4.79	4.3	13.73
ROE	0.06	0.07	-0.12	0.11	0.1
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q4

Metric	2022-03-31	2022-06-30	2022-09-30	2022-12-31	2023-03-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.01	0.01	0.01	0.01	0.01
Net income per share	0.01	0.01	0.01	0.01	0.01
Operating cash flow per share	0	0	0	0	0
Free cash flow per share	0	0	0	0	0
Cash per share	0.04	0.04	0.28	0.03	0.03
Book value per share	0.41	0.19	0.42	0.21	0.43
Tangible book value per share	0.41	0.42	0.42	0.43	0.43
Share holders equity per share	0.41	0.19	0.42	0.21	0.43
Interest debt per share	0.03	0.03	0.03	0.03	0.04
Market cap	246.3M	288.61M	200.89M	236.95M	200.96M
Enterprise value	219.73M	189.76M	193.86M	134.55M	201.78M
P/E ratio	2.93	3.15	2.19	1.42	1.2
Price to sales ratio	16.17	16.93	11.78	12.32	10.44
POCF ratio	270.37	-167.46	-116.56	102.42	86.86
PFCF ratio	-63.11	-167.46	-116.56	-238.15	-201.97
P/B Ratio	0.21	0.52	0.17	0.37	0.16
PTB ratio	0.21	0.52	0.17	0.37	0.16
EV to sales	14.43	11.13	11.37	6.99	10.49
Enterprise value over EBITDA	-75.64	-84.71	-86.54	-1.77K	-2.66K
EV to operating cash flow	241.19	-110.1	-112.48	58.16	87.22
EV to free cash flow	-56.3	-110.1	-112.48	-135.23	-202.8
Earnings yield	0.09	0.08	0.11	0.18	0.21
Free cash flow yield	-0.02	-0.01	-0.01	0	0
Debt to equity	0.07	0.16	0.08	0.16	0.08
Debt to assets	0.06	0.07	0.07	0.07	0.07
Net debt to EBITDA	9.15	44.13	3.14	1.35K	-10.83
Current ratio	3.03	16.19	16.19	3.13	3.13
Interest coverage	-1.46	-1.17	-1.17	-0.6	-0.6
Income quality	0.04	-0.08	-0.08	0.06	0.06
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.4	0.36	0.36	0.35	0.35
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	-5.28	0	0	-1.43	-1.43
Capex to revenue	-0.32	0	0	-0.17	-0.17
Capex to depreciation	-2.13	0	0	-1.45	-1.45
Stock based compensation to revenue	0	0	0	0	0
Graham number	0.26	0.19	0.28	0.26	0.37
ROIC	0	-0.01	0	0	0
Return on tangible assets	0.02	0.02	0.02	0.03	0.03
Graham Net	-0.01	-0.01	0.23	-0.02	-0.02
Working capital	130.32M	823.33M	823.33M	121.65M	121.65M
Tangible asset value	1.16B	1.2B	1.2B	1.28B	1.28B
Net current asset value	42.21M	728.35M	728.35M	15.36M	15.36M
Invested capital	0.07	0.16	0.08	0.16	0.08
Average receivables	0	0	0	0	0
Average payables	6.46M	6.07M	5.69M	6.16M	6.63M
Average inventory	8.47M	6.29M	4.11M	3.57M	3.02M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	69.53	49.79	49.79	57.21	57.21
Days of inventory on hand	91.16	35.99	35.99	26.03	26.03
Receivables turnover	0	0	0	0	0
Payables turnover	1.29	1.81	1.81	1.57	1.57
Inventory turnover	0.99	2.5	2.5	3.46	3.46
ROE	0.02	0.04	0.02	0.07	0.03
Capex per share	0	0	0	0	0

0858.HK Frequently Asked Questions

What is Extrawell Pharmaceutical Holdings Limited stock symbol ?

Extrawell Pharmaceutical Holdings Limited is a HK stock and trading under the symbol 0858.HK

What is Extrawell Pharmaceutical Holdings Limited stock quote today ?

Extrawell Pharmaceutical Holdings Limited stock price is $0.033 today.

Is Extrawell Pharmaceutical Holdings Limited stock public?

Yes, Extrawell Pharmaceutical Holdings Limited is a publicly traded company.

Something similar

Top by Market Cap

VTSAX

Company Profile

Volume Average 787.42K
Market Capitalization 78.87M
Employee 169
CEO Dr. Yi Xie Ph.D.
Headquarters Quarry Bay,HK
IPO Date 1999-03-10
Website https://www.extrawell.com.hk

Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China. The company operates through Manufacturing, Trading, and Gene Development segments. It offers transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. The company also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. In addition, it is involved in the marketing and distribution of imported pharmaceutical products, including Millibar for the treatment of high blood pressure; and development of oral insulin. Further, the company engages in the commercial exploitation and development of genome-related technology; provision of agency services; property investment business; and holding of gene invention rights. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.